

Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022



Phone: +44 20 8123 2220
Fax: +44 207 900 3970
office@marketpublishers.com
<https://marketpublishers.com>

Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022

Date:	February 1, 2017
-------	------------------

Pages:	170
--------	-----

Price:	US\$ 2,000.00
--------	---------------

ID:	PA39CD454DBEN
-----	---------------

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Oncological segment has gained a great momentum with the advent of modern technologies and the better equipped sequencing methodology. Over the past years, there has been gradual paradigm shift from traditional medicine and accelerated acceptance towards the precision medication. Physicians are opting for the personalization of the medicines according to the genomic makeup of the patient.

During the last decade, great efforts have been made to develop immunotherapeutic approaches for the treatment of malignant diseases as alternatives to traditional chemotherapy and radiotherapy. A quintessential goal of immunotherapy in cancer is treatment with vaccines that elicit potent anti-tumor immune responses without side effects. The upsurge of immunotherapeutics in oncology is remarkable and the trail towards getting personalized is in future trends. With the development of the pharmacogenomics and genome mapping resolutions towards human genome are making personalized vaccines to be more efficacious. The platform for the personalization of vaccines had been built by the human genome project.

Geographically, the acceptance of personalization is greater in the western world as both the new and old vaccine approaches towards the cancer are transforming the landscape of the major markets of western world including US, Western Europe and Japan. In contrary the concept is less influential in the low and middle income countries. Nevertheless, in the upcoming time the improvement will surely administer the challenges of cost and distribution which will aid the personalization in the Asia-Pacific regions.

The personalized cancer vaccine will be beneficial to the patients as the treatment will be generated personally for the individual which will target the fundamental driver of their disease while also potentially avoiding toxicity. In terms of cost and savings the payers found personalization to be attractive as mechanism to control usage of expensive drugs and can avoid the wasteful expenditure on treatments that are ineffective.

In contrary, it also provides better future opportunities for pharmaceuticals too although there are several challenges and unmet needs which has to be defined first. Many pharmaceutical companies have calculated the improvised vision for the right drug, right patient and the right time. This concept saves the resources, time and provides ample opportunities to achieve substantial medications for the investors.

The future potential of personalized cancer vaccines for the detection, management and preventing diseases is primarily dependent on the ongoing genomic projects, merging translational medicines and advances in personal genetic testing and developing targeted therapy. Such innovative therapies are also welcomed by the physicians as these approaches minimize the trial and error diagnosis and treatment. The personalized cancer vaccine will be beneficial to the patients as the treatment will be generated personally for the individual which will target the fundamental driver of their disease while also potentially avoiding toxicity. In terms of cost and savings the payers found personalization to be attractive as mechanism to control usage of expensive drugs and can avoid the wasteful expenditure on treatments that are ineffective.

The report "Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022" is an inclusive report which covers the current and future opportunities for the personalized cancer vaccines and its varied inclinations in oncology. The report throws a light over the clinical relevance of personalized forms and

identifies the risk and commercial aspects along with the potential outcome for the success of personalized cancer vaccines in the upcoming future directions.

“Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022” Report Highlights:

- Introduction to Personalized Cancer Vaccines
- Identification of Tumor Neoantigens
- Development & Mechanism of Personalized Vaccines
- Categories of Personalized Cancer Vaccines
- Biomarkers for Personalized Vaccines
- Personalized Vaccines for Multiple Cancers
- Current & Future Market Outlook of Personalized Cancer Vaccines

Table of Content

1. PERSONALIZED VACCINE: TRAIL TOWARDS CANCER

- 1.1 Prologue to Personalized Cancer Immunotherapy
- 1.2 Advent of Personalized Cancer Vaccine

2. PERCEPTION OF PERSONALIZED VACCINOMICS

- 2.1 Genetic Heterogeneity by HLA System
- 2.2 Genesis of Tumor Neoantigens

3. IDENTIFICATION OF TUMOR NEOANTIGENS

- 3.1 Conventional Methodologies
- 3.2 Next Genome Sequencing Approach

4. DEVELOPMENT OF PERSONALIZED VACCINES

- 4.1 Development Process of Personal Cancer Vaccine
- 4.2 Economic Aspects of Personalized Cancer Vaccine

5. MECHANISM OF PERSONALIZED VACCINES

- 5.1 Rationale of Personal Cancer Vaccine
- 5.2 Neoantigens & Immune Interactions

6. APPLICATION OF NEOANTIGENS IN THERAPEUTICS

- 6.1 Adoptive T Cell Therapy
- 6.2 Checkpoint Blockade

7. CATEGORIES OF PERSONALIZED CANCER VACCINES

- 7.1 Personalized Peptide Vaccination (PPV)
- 7.2 DNA Cancer Vaccines
- 7.3 RNA Based Vaccines
- 7.4 Dendritic Cell Vaccines
- 7.5 Whole Tumor Cell Vaccines
- 7.6 Recombinant Virus Vaccines

8. BIOMARKERS FOR PERSONALIZED VACCINES

- 8.1 Pharmacogenomic Biomarkers
- 8.2 Prognostic & Predictive Biomarkers
- 8.3 Immune Checkpoint Biomarkers

9. PERSONALIZED VACCINES FOR VARIED CANCERS

- 9.1 Melanoma
- 9.2 Lung Cancer
- 9.3 Breast Cancer
- 9.4 Colorectal Cancer
- 9.5 Leukemia
- 9.6 Prostate cancer
- 9.7 Cervical Cancer
- 9.8 Gastric Cancer
- 9.9 Brain Tumor
- 9.10 Renal Cancer

10. PHARMACOGENOMICS OF PERSONALIZATION

- 10.1 Pharmacogenomics towards Genomic Polymorphism
- 10.2 Somatic Mutations in Cancer Pharmacogenomics
- 10.3 Applications of Pharmacogenomics

11. PERSONALIZED VACCINES MARKET OVERVIEW

- 11.1 Market Trends Towards Therapeutic Personalization
- 11.2 Mergers & Acquisitions for Personalized Therapy

12. GLOBAL PERSONALIZED VACCINES MARKET DYNAMICS

- 12.1 Personalization Growth Drivers
 - 12.1.1 Increasing Cancer Incidences
 - 12.1.2 Cancer Heterogenetic Environment
 - 12.1.3 High Level of Specificity
 - 12.1.4 Government Initiatives
 - 12.1.5 Reduced Genome Sequencing Cost & Time
 - 12.1.6 Sustained Level of Innovation
- 12.2 Personalization Major Challenges

13. GLOBAL PERSONALIZED CANCER VACCINES MARKET FUTURE ASPECTS

14. COMPETITIVE LANDSCAPE

- 14.1 Advaxis Inc.
- 14.2 Avax Technologies
- 14.3 BioNtech
- 14.4 Celldex
- 14.5 Genentech Inc.
- 14.6 Genocea
- 14.7 ISA Pharmaceuticals
- 14.8 Merck & Co.
- 14.9 Moderna
- 14.10 Neon Therapeutics

LIST OF FIGURES

- Figure 1-1: Categorization of the Cancer Immunotherapeutics Towards Cancer Vaccines
- Figure 1-2: Illustration of Advantages Provided by the Targeting Neoantigens
- Figure 2-1: Distinguishing Features of Driver & Passenger Gene Mutations
- Figure 3-1: Identification of Tumor Antigens by Conventional Approach
- Figure 3-2: Number of Mutation Derived Neoantigens in Human Cancer
- Figure 3-3: Identification of Tumor Specific Neoantigens by Next Generation Sequencing
- Figure 4-1: Illustration of Development of personalized Cancer Vaccines
- Figure 4-2: Estimated Cost for Cancer Cell's Genome Sequencing (US\$)
- Figure 4-3: Estimated Economic (US\$) & Timeline (Weeks) Projections of Personalized Cancer Vaccine
- Figure 5-1: Illustration of Development of Personalized Cancer Vaccines
- Figure 5-2: Immune Stimulation by T-Cells with Personalized Cancer Vaccine
- Figure 5-3: Immune Response Stimulation by B Cells with Personalized Cancer Vaccines
- Figure 6-1: Route of Action of Adoptive T-Cell Mechanism in Individual
- Figure 6-2: Clinical Aspects of Tumor Infiltrating T Cells in Cancer
- Figure 6-3: Typical Mechanism of T Cell Activation via Signal Binding
- Figure 6-4: Schematic Representation of Evolution of CARs Design
- Figure 6-5: Mechanism of Cell Checkpoint Blockade in Cancer Vaccines
- Figure 6-6: Mechanism of Cytotoxic T-Lymphocyte Associated Antigen-4 (CTLA-4)
- Figure 6-7: Mechanism of PDL-1 Checkpoint Blockade in Tumor Cells
- Figure 7-1: Differences between Conventional & Personalized Peptide Vaccine
- Figure 7-2: The Representation of Template of a Polypeptide DNA Vaccine
- Figure 7-3: Principle Structure of Synthetic m-RNA Developed with Specific Antigen
- Figure 7-4: Representation of Ex-Vivo Preparation of Dendritic Cell based Vaccines
- Figure 7-5: The Tumor Microenvironment Suppresses Efficacy by DC based Vaccines
- Figure 7-6: Mechanism of Personalized Autologous Whole Tumor Cancer Vaccine
- Figure 7-7: Representation of Replicative Virus Encoding a HSP Gene for Antitumor Activity
- Figure 8-1: Illustration of Various Types of Biomarkers in Personalized Medicine
- Figure 8-2: Roadmap of Development of Predictive Biomarkers
- Figure 8-3: High Throughput Immune Assessment for Biomarker Discovery
- Figure 9-1: Alterations in Mechanism of Cell Cycle Control of CDKN2A
- Figure 9-2: Illustration of Targetable Oncogenic Drivers in Non-Small Lung Cancer
- Figure 9-3: Personalized Strategies to Attain the Target of Interest in Acute Myeloid Leukemia
- Figure 9-4: Prevalence of Cervical Cancer in Women in Developed & Developing Countries
- Figure 9-5: Proportion of Genetic Abnormalities Present in Gastric Cancer
- Figure 9-6: Classification of Gliomas into Four Grades Based as WHO Classification
- Figure 9-7: Illustration of Loss of VHL Expression Leads to Renal Cell Carcinoma
- Figure 10-1: Demonstration of Genomic Polymorphism in Pharmacogenomics
- Figure 10-2: The Sources of Pharmacological & Pharmacogenetic Variability's
- Figure 10-3: Applications of Pharmacogenomics in Cancer Precision Medicines
- Figure 11-1: Personalized Cancer Vaccine Market Opportunity Assessment (US\$ Million), 2017-2022
- Figure 11-2: Representation of the Commercial Oncological Trials by Segment
- Figure 12-1: Representation of Growth Drivers in Personalized Cancer Vaccines
- Figure 12-2: Illustrations of the Reduced Sequencing Cost of Human Genome
- Figure 12-3: Major Challenges faced by the Personalized Cancer Vaccines

I would like to order:

Product name: Personalized Cancer Vaccines Market & Clinical Innovation Outlook 2022
Product link: <https://marketpublishers.com/r/PA39CD454DBEN.html>
Product ID: PA39CD454DBEN
Price: (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click 'BUY NOW' button on product page <https://marketpublishers.com/r/PA39CD454DBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
E-mail:
Company:
Address:
City:
Zip/Post Code:
Country:
Tel:
Fax:
Your message:

* All fields are required

Customer Signature _____

Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms_conditions.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to **+44 20 7900 3970**